Sorrento Therapeutics Inc (SRNE)

[urkidding1]

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) recently announced additional positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (PSC-CP-004) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for three infusions for a total of 1 x 10 6 cells/kg. The primary objective is to evaluate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS.

On January 26, 2021 , Sorrento announced the first three enrolled ICU COVID-19 patients were discharged from the hospital within a week of starting COVI-MSC infusions and a fourth patient just started the COVI-MSC treatment last Monday, January 25, 2021 . The fourth patient who had been in the hospital for more than 2 weeks and required intubation and mechanical ventilation with worsening pulmonary compromise received 3 infusions of COVI-MSC and improved so rapidly that he was able to be discharged the evening after his 3 rd infusion on January 29, 2021 . No infusion related safety events were reported. Dr. Eyad Almasri , Associate Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine at UCSF Fresno, is the principal investigator in this ongoing study.